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Abstract
Background Cellular dermatofibromas (CDF) are an uncommon variant of benign fibrous
histiocytomas with propensity to recur and rarely metastasize as well as demonstrate
histologic similarities to more dangerous lesions.
Objectives The aim of this present study was to further describe the presentation and
outcome of the cellular variant of benign fibrous histiocytomas so that it can be diagnosed
and treated appropriately.
Methods A retrospective chart review was performed on all patients seen in a single
hospital system in Detroit, Michigan, from 2007 to 2017. CDF was confirmed by pathology.
Baseline demographics, specialty service of diagnosis and treatment, treatment modality,
and outcome were collected.
Results Of the 93 qualifying patients, the average age at diagnosis was 42.65 years. The
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most common specialty service that diagnosed and treated patients was dermatology
(38.71%). About 95.0% of CDF stained positive for Factor 13A (19/20), and 90.48% were
CD34 negative (19/21). Of patients, 33.33% had recurrences of their CDF (9/27). Two
patients had three or more recurrences. One patient’s death was attributed to the CDF.
Conclusion CDF have a high local recurrence rate and similarities to more dangerous and
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malignant lesions. Patients with cellular dermatofibromas present to many subspecialty
services for diagnosis and should be treated aggressively.

Introduction
Cellular dermatofibromas (CDF), also known as “cellular fibrous
histiocytomas” or “atypical dermatofibromas”, are an uncommon
variant of benign fibrous histiocytoma (BFH; dermatofibroma),
which were first described in a series of case reports in 1994.1
Patients with CDF often present with hyperpigmented papules
with central hypopigmentation (Fig. 1). While BFH rarely recurs
after incomplete excision, several reports have documented the
rate of local recurrence of CDF ranging anywhere from 17 to
50%.1–3 There have also been several reports of CDF metastasizing and sometimes resulting in death.4–8 In this retrospective
study, we sought to further describe the patient demographics,
clinical characteristics, treatment modalities, recurrence rates,
and specialty services that most frequently encounter cellular
dermatofibromas, therefore helping to facilitate early recognition
and treatment of this potentially aggressive diagnosis.

Methods
A retrospective chart review was performed on all patients diagnosed with cellular dermatofibroma who were seen by the Henry
ª 2019 The International Society of Dermatology

Figure 1 Cellular dermatofibroma on patient’s shoulder
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Figure 2 Flowchart of patients included in the study
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Ford Health System from 2007 to 2017. The study was approved
by the Institutional Review Board at Henry Ford Health System. A

system (Co-Path) was performed on all patients over the aforementioned 10-year period using the following keywords: “Cellular

natural language search of the dermatopathology medical record

dermatofibroma”, “Dermatofibroma with cellular features”, and
“Cellular fibrous histiocytoma.” Only patients with an official

Table 1 Patient demographics and distribution of lesions

Age (years)
Gender
Female
Male
Race
Unknown
Caucasian
African-American
Hispanic
Indian
Arabic
Location of cellular dermatofibroma
Extremity
Trunk
Acral
Face
Scalp
Neck

42.65  16.7
(range 6–85)

pathology diagnosis of CDF were included in the study. The
records of each patient were reviewed for baseline demographics, clinical characteristics, specialty service of diagnosis and
treatment, treatment modality, and outcome with special attention
paid to any patients with recurrence(s) of their CDF. The age of
the patient was recorded at the time of the original biopsy, which

51 (54.84%)
42 (45.16%)

confirmed the diagnosis of CDF.

32
29
23
3
2
2

(34.41%)
(31.18%)
(24.73%)
(3.26%)
(2.15%)
(2.15%)

Results

43
24
12
7
5
2

(46.24%)
(25.81%)
(12.90%)
(7.53%)
(5.38%)
(2.15%)

of 93 patients with pathology-proven cellular dermatofibromas

A total of 116 patients were identified using the described
search terms. Of these, 12 were duplicate patients (because of
re-excisions and recurrences) and 11 were excluded from the
study because of inappropriate diagnoses, which yielded a total
(Fig. 2). Average age at diagnosis was 42.65 years (standard
deviation [SD] = 16.7 years) (Table 1 & Fig. 3). The majority of
patients were female (54.84%) and Caucasian (31.18%), with
the most common location of the CDF being on the extremity
(46.24%) or trunk (25.81%) (Table 1).

Figure 3 Age and gender of patients reviewed with cellular dermatofibromas
ª 2019 The International Society of Dermatology

International Journal of Dermatology 2020, 59, 229–235

231

232

Report

Siegel et al.

Retrospective review of cellular dermatofibromas

Table 2 The number of patients with immunohistochemistry
findings on the samples that were studied

Figure 4 Histopathologic characteristics of cellular
dermatofibromas. Key histopathologic findings suggestive of CDF
include a large cellular collection in the dermis (hematoxylin-eosin
stain [H&E], 940) (a) with a storiform arrangement (H&E, 9100)
(b). Additionally, CDF demonstrate collagen trapping normally
visualized in dermatofibromas (H&E, 9100) (c). CDF can extend
deep even to the subcutaneous fat but has minimal infiltration into
the septae and lobules (H&E, 9100) (d)

CDF are recognized by histopathologic features including
spindle cell proliferations with storiform appearance, peripheral
collagen trapping, and increased cellularity with fibrohistiocytic
cells (Fig. 4). These tumors also tend to be larger than BFH
and extend to the deep dermis or into the subcutis. Of the 93

Desmin
Factor 13A
CD34
Vimentin
S100
CD163
CD68
EMA
CD1a
CD31
Cytokeratin
BCL2
Smooth muscle actin
CD10
Factor 8
M181
SMA
MelanA
Beta Catenin
AE1/AE3
Sox10
HMB45
CD99
PGP 9.5
HHF35
Pan keratin
KP-1

Positive

Negative

Total
studied

0
19
3 (1 indeterminate)
4
1
5
3
1
0
0
0
1
1
3
0
3 (all low)
4
0
1
0
0
0
1
1
0
0
0

7
1
19
0
16
0
2
3
2
2
9
0
2
0
1
0
1
2
1
3
3
1
0
0
1
1
1

7
20
21
4
17
5
5
4
2
2
9
1
3
3
1
3
5
2
2
3
3
1
1
1
1
1
1

patients diagnosed with CDF, 29 of them had some form of
immunohistochemistry (IHC) performed on their tissue sample(s).
and 90.48% were CD34 negative (19/21). Additionally, 94.12%

(average = 3.93; range = 2.0–6.0; SD = 1.33), and surgical
excision was defined as a treatment when the patient was taken

were S100 negative (16/17), 100% were desmin negative (0/7),

to the operating room and put under general anesthesia. Of the

4/4 were vimentin positive, 5/5 were CD163 positive, and 3/5
were CD68 positive (Table 2 and Fig. 5).

patients that had recurrences (9), five had been treated via re-

Of those studied, 95.0% were positive for Factor 13A (19/20),

Margins were evaluated and commented on in 62/93 cases

excision, one via Mohs micrographic surgery, one via wide local
excision, and two had no re-excision after the original biopsy.

(67.7%). The margins were noted to be positive either lateral

Of the original 93 patients included in our study, three passed

and/or deep in 51/62 cases (82.3%) and negative in 11/62

away during the study timeframe. One death was attributed to

(17.7%). About 8/9 patients with recurrent lesions were noted to

the underlying CDF as there was sarcomatous extension into
the chest wall with recurrent bleeding. The other two deaths

have positive lateral and/or deep margins (88.9%).
The majority of patients were seen and treated by Dermatol-

were attributed to unrelated causes: acute myocarditis with res-

ogy (38.71%). The remaining patients were treated by Plastic
Surgery (19.35%), General Surgery (13.98%), Family Medicine

piratory distress syndrome (one) and natural passing (one).

(7.53%), Orthopedics (2.15%), Podiatry (2.15%), Internal Medi-

with the primary service that cared for their CDF. Of the 27

cine (1.08%), and Hematology & Oncology (1.08%) (Fig. 6).

patients that did follow-up with their primary service for two or

Fifty-one patients never followed up after diagnosis or treatment

The most common treatment modality was no re-excision

more appointments or over the span of two or more years, nine

after the original biopsy (27.84%) followed by wide local excision (23.71%), which, when documented, had average proce-

had recurrences of their CDF (33.33%). The average recurrence occurred at 14.56 months after original treatment

dure margins of 24.38 mm (range = 10–60; SD = 22.59). Other

(range = 1–60; SD = 15.59). Two patients had three or more

treatment modalities included re-excision (18.56%), Mohs surgery (6.19%), or surgical excision (2.06%) (Fig. 7). Re-excision

recurrences. The most striking feature that was noted on the

was defined as a procedure with margins less than 10 mm

margins, which was found in 8/9 cases.

International Journal of Dermatology 2020, 59, 229–235
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dermatofibromas are generally considered a benign tumor, the
cellular variant has been reported to have a significant tendency
for recurrence after local excision and was found to recur in
33.33% of cases in the present study. Furthermore, because
this study had a significant proportion of patients who were lost
to follow-up (55.67%), the recurrence rate of CDF may be even
higher than what we have reported.
The majority of patients with recurrent CDF were treated with
either re-excision or Mohs micrographic surgery (6/9 patients),
both of which have narrow margins of up to 10 mm. Furthermore, 8/9 recurrent cases were found to have positive deep
and/or lateral margins. These findings suggest that a larger
excision greater than 10 mm may be a more appropriate treatment modality. This information is relevant to all medical specialties as 61.29% of the patients in this study were diagnosed
and treated by providers who did not practice dermatology.
Figure 5 Cellular dermatofibroma immunohistochemistry (IHC)
stains. IHC stains frequently employed to identify cellular
dermatofibromas include positive factor XIIa (940) (a) and positive
CD163 (940) (b). CD34 is often used to differentiate CDF from
dermatofibrosarcoma protuberans (940) (c); however, at times this
stain can be positive deeply near the fat

In the literature, there have been a total of 11 documented
cases involving CDF metastasizing to organs such as the lungs,
lymph nodes, soft tissues, and liver.8 Although we did not have
any patients with distant metastases in our retrospective study,
we cannot be certain that this did not occur in the patients who
were lost to follow-up. Additionally, while we did not encounter
any patients with distant metastases, one patient’s death was

Discussion

thought to be because of aggressive local tumor growth result-

all benign fibrous histiocytomas (BFH; dermatofibroma), the

ing in acute hemorrhage, anemia, and thrombocytopenia.
There are several features that help to distinguish the CDF

most common cutaneous spindle cell neoplasm.9 Although the

variant from the BFH. These include an average larger size

exact etiology of all dermatofibromas is unknown, they are

(2 cm vs. 0.8 cm), higher cellularity, increased mitotic rate, pos-

thought to represent both a reactive and/or neoplastic process.
CDF are most commonly found on the extremities, but they

sible presence of focal necrosis, limited cellular polymorphism,

10

can also develop on the face, ears, scalp, hands, and feet.

of these features, CDF may initially be misdiagnosed as der-

Females are affected slightly more frequently than males, espe-

matofibrosarcoma protuberans (DFSP) or leiomyosarcoma.

Cellular dermatofibromas (CDF) constitute approximately 5% of

cially

those

in

their

middle

age.9

While

cutaneous

and common extension into the superficial fascia.9,11 Because

Immunohistochemistry

stains

can

be

employed

to

help

Figure 6 Distribution of the specialties that diagnosed and treated patients with cellular dermatofibromas
ª 2019 The International Society of Dermatology
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Figure 7 Absolute number of patients treated by modality

differentiate between these similar-appearing lesions. CDF have

recurrence rate and similarities to more aggressive and malig-

been found to predominately stain positive for factor 13a,

nant lesions. This study did not identify any key clinical or histol-

whereas DFSP more commonly express CD34 (Fig. 3).12,13 An

ogy features to differentiate the recurrent cases from those that

additional IHC stain that can be helpful in distinguishing CDF

did not recur; however, the cases that recurred tended to have

from DFSP is CD163, which is a marker for monocytes, macro-

positive lateral and/or deep margins, which highlights the impor-

phages, and histiocytes. Our findings were consistent with what
has been shown in the literature, in that of the CDF that were

tance of complete excision. For these patients, the authors recommend re-excision of the lesion with margins >10 mm and

stained with IHC, 95.0% were positive for factor 13a, 90.48%

close follow-up. Additional data and studies are needed to bet-

were CD34 negative, and 100% were positive for CD163. We

ter define specific treatment recommendations for these lesions.

propose using factor 13a, CD34, and CD163 as the initial stains
for lesions concerning for CDF on histology.
Although this review provides important characteristics about
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the uncommon cellular variant of BFH, there were several limi-
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in the patients’ charts. Only 24.7% of patients had immunohistochemistry performed on their CDF biopsy, and the stains used
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Conclusion
Given the available literature and the results of this review, it is
appropriate to counsel patients with CDF on the high local
International Journal of Dermatology 2020, 59, 229–235
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